Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Cell Cryopreservation for Lymphocytes Improves Hematopietic Cell Survival

Technology #98119

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Collections
Image Gallery
LymphocyteBone Marrow Transplant Cell Cryopreservation
Categories
Researchers
Allison Hubel, PhD
Professor, Department of Mechanical Engineering, School of Science and Engineering
External Link (www.me.umn.edu)
Managed By
Kevin Anderson
Technology Licensing Officer 612-624-8293
Patent Protection
US Patent 7,112,576

Cell Cryopreservation of Lymphocytes for Post Bone Marrow Transplant Treatment of Tumors

A method has been developed that utilizes cryopreservative agents for improving the survivability of hematopoietic cells when frozen. Using a balanced electrolyte solution with an arabinogalactan equivalent, a high-survival rate of hematopoietic cells is maintained. It contains a much smaller concentration of glycerol compared to other methods and does not use DMSO, thus decreasing cell loss due to osmotic stress and DMSO toxicity. This technique will increase effectiveness of cell therapeutics by increasing cell viability following cryopreservation. Overall, this cell cryopreservation method will enhance lymphocyte treatments for tumors, especially following bone marrow transplants, as well as treatments for viral infections.

MN-IP Try and Buy
Try
  • This technology is available for an immediate license.
Buy
  • Exclusive license for a $50,000 payment.
  • No patent expenses.
  • 1.5% royalty after $1 million in product sales. 1.0% for MN companies.

** View the Term Sheet **
** Contact Kevin Anderson for specific details. **

Lymphocytes as a Cell Therapeutic

An enhanced method of cell cryopreservation for lymphocytes could enhance treatment efficacies for lymphocyte-based treatments. Lymphocytes show great promise as a cell therapeutic for tumors and viral infections, especially when used as an adjuvant during bone marrow transplantation. Once these cells have been modified ex-vivo for the specific clinical application, the cells are cryopreserved to maintain cell viability and to pool the cells to reach the dose required for clinical therapies. However, current methods for cryopreservation of lymphocytes do not maintain adequate cell viability. Cell loss is seen in glycerol-based methods through the creation of cellular osmotic stress and through DMSO-based methods because of DMSO toxicity. A need exists for a method that decreases the cellular loss seen in current hematopoietic cell cryopreservation methods.

BENEFITS OF CRYOPRESERVATION METHOD OF PERIPHERAL BLOOD LYMPHOCYTES:

  • Increased cell viability following cell preservation compared to current cell preservation techniques
  • Decreased risk for cell loss due to glycerol induced osmotic stress
  • No risk for cell loss due to DMSO toxicity